Skip to content

Clinical efficacy and safety of microneedles with nitric oxide source complex solution in the treatment of non-menopausal female pattern hair loss

Clinical efficacy and safety of microneedles with nitric oxide source complex solution in the treatment of non-menopausal female pattern hair loss

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077392
Enrollment
Unknown
Registered
2023-11-07
Start date
2023-11-10
Completion date
Unknown
Last updated
2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

female pattern hair loss

Interventions

microneedles combined with nitric oxide source complex solution group:microneedles combined with nitric oxide source complex solution
simple topical minoxidil solution group:simple topical minoxidil solution
microneedles combined with minoxidil solution group:microneedles combined with minoxidil solution

Sponsors

Beijing Friendship Hospital,Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1, Ages 18-45, Sinclair II,III non-menopausal female pattern hair loss 2. Female patients with normal endocrinology, thyroid function and antibodies, hemoglobin, serum iron, ferritin and gynecologic ultrasound, and regular menstruation; 3. No topical use of hair growth drugs and other topical treatments within 3 months prior to treatment; 4. No systematic use of hair-generating drugs within 3 months prior to treatment; 5.have good compliance, can regularly participate in the interview.

Exclusion criteria

Exclusion criteria: 1, pregnant or lactating women, menopausal women, menstrual disorders; 2, other types of hair loss,such as alopecia areata, hair loss caused by ringworm; 3, severe systemic disease, anemia,low blood pressure, history of thyroid, polycystic ovaries, or elevated blood potassium; 4. Scalp hair follicles have atrophied so that hair cannot be generated; 5, can not be prescribed regularly, so that it is impossible to judge the efficacy or incomplete data 6. Infection exists in the area of microneedle acupuncture; 7, abnormal clotting function; 8, allergic to the test drug and its ingredients; 9. Researchers who are participating in other clinical trials; 10. The investigator considers it inappropriate to participate in this researcher.

Design outcomes

Primary

MeasureTime frame
hair density and hair shaft diameter under dermatoscope;

Secondary

MeasureTime frame
Sinclair's stage change ; 7-point global-assessment scale;hair shedding score;the women's androgenetic alopecia quality of life questionnaire;patients' satisfaction;

Countries

China

Contacts

Public ContactZhuo Fenglin

Beijing Friendship Hospital,Capital Medical University

zflsunny@hotmail.com+86 159 1089 5068

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026